Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf Mounjaro is not working the way you expected, you're almost certainly not doing anything wrong. Weight loss on tirzepatide tends to follow a specific biological pattern, and a week or two of no movement on the scales is a normal part of that process rather than a sign of failure. That said, there are real, fixable reasons why some people stall for longer, and a prescriber review can usually identify them. These are prescription-only medicines; a clinician has to assess what's happening before anything changes.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen of Mounjaro contains 2.5mg tirzepatide per dose. That starting strength exists so your body adjusts to the medicine gradually, reducing the chance of nausea. Its job is not weight loss. Many people pick up that first pen expecting results within a fortnight, weigh themselves on day ten, and conclude Mounjaro isn't working for them, a situation we cover in detail for anyone who wants to understand why Mounjaro may not seem to be working and what to do about it. It's an understandable assumption, but it's based on the wrong dose.
Titration typically takes three to four months before most people reach doses in the 7.5mg to 10mg range, where clinical trials recorded the larger reductions. In SURMOUNT-1, average weight loss of around 20% was seen at 15mg after 72 weeks, not 72 days. If you're on week six at 5mg and the scales haven't shifted dramatically, you're still early in a year-long clinical journey. The timeline for Mounjaro to work is measured in months, not weeks, and that's not a disclaimer, it's what the trial data actually show.
A prescriber can tell you whether you're at an appropriate dose for the time you've been on treatment, and whether moving up is clinically the right call.
Tirzepatide reduces appetite and slows gastric emptying) two mechanisms that make eating less easier. What it cannot do is override a significant caloric surplus or compensate for patterns that work against weight loss. The most common culprits our prescribers hear about are: liquid calories that aren't counted (soft drinks, juices, alcohol), meals that have quietly expanded now that eating feels more comfortable, and insufficient protein, which matters because Mounjaro-related weight loss includes some lean muscle mass alongside fat.
Sleep is also relevant and often overlooked. Poor or short sleep raises ghrelin and disrupts the hormones that Mounjaro is partly working through. This doesn't mean you need to overhaul your life overnight. It means that if the medicine has reduced your appetite but your weight hasn't moved in six weeks, it's worth looking at what's landing on the plate and whether your sleep pattern has changed.
Activity level plays a role too, though strength training specifically helps protect muscle. The full Mounjaro treatment guide covers the lifestyle factors that complement the medicine, which are part of the licensed indication for a reason.
Even when everything is going well, the rate of weight loss on tirzepatide typically slows as your body reaches a new lower weight and adapts. This is metabolic adaptation, not the medicine failing. A two-to-four week plateau mid-treatment, especially after a dose stabilisation, is expected. A plateau lasting three or more months at a stable dose, with no dietary or activity explanation, is something different.
If you're wondering whether tirzepatide genuinely isn't working for you rather than just working slowly, the markers to look at are: time on treatment, current dose, any changes in side-effect profile (reduced nausea may signal the body adapting), and whether weight has been completely static or simply slower than expected. Completely static weight over several months at a maintained therapeutic dose does warrant a prescriber conversation.
NICE guidance (TA1026) notes that if less than 5% weight loss occurs after six months at the highest tolerated dose, continuing should be reviewed. That's a clinical benchmark, not a finish line. A review at that point might result in a dose change, a lifestyle referral, or a decision about continuing, none of which you should make alone.
The one thing that consistently delays progress is people adjusting things themselves: skipping doses, cutting the dose, or stopping entirely because they've decided the medicine isn't for them. If you're concerned about Mounjaro's effect on your weight loss specifically, a structured review is far more useful than a self-directed change.
Stopping suddenly has its own implications; if you've been wondering about how to come off Mounjaro responsibly, that process is also something a prescriber should guide. The clinical team at nume reviews every repeat prescription individually, which creates a natural checkpoint, but you can contact our aftercare team any time if you're concerned about your progress, without waiting for the next order. Our FAQs page also covers some of the most common progress questions people raise between reviews.
For wider context on how weight-loss treatment works alongside lifestyle changes, the NICE appraisal of tirzepatide (TA1026) and the NHS tirzepatide medicines page both set out the clinical picture plainly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.